CLINUVEL Pharmaceuticals Ltd announced that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq Stock Market later today under the ticker symbol CUVL. The move follows the U.S. Securities and Exchange Commission (SEC) declaring the company’s 20-F Registration Statement effective on July 17 and receiving approval from Nasdaq to list the ADS. This upgrade enhances CLINUVEL’s visibility among U.S. investors and aligns with its strategic shift toward North America.

The company’s existing over-the-counter American Depositary Receipt (OTC: CLVLY) will be upgraded from Level I to Level II as an ADS traded on the Nasdaq Global Select Market. Each CUVL ADS represents one ordinary share of CLINUVEL listed on the Australian Securities Exchange (ASX: CUV). CLINUVEL stated it does not propose to raise any capital or issue new shares as part of the upgraded depositary share program. Holders of CLVLY are not required to take any action to convert their ADRs to CUVL.

Strategic and Market Implications

The Nasdaq Global Select Market offers greater visibility among U.S. investors and access to specialised analytics provided by Nasdaq. Professor Jeffrey Rosenfeld, CLINUVEL’s Chairman, highlighted the significance of the uplisting, stating it marks an important step for the company’s visibility in U.S. capital markets and reflects a broader shift of its business toward North America. He noted that the gradual shift to the U.S. makes sense as the company matures.

Key Details of the Uplisting

Regulatory and Risk Factors

The registration of CLINUVEL’s securities under the U.S. Securities Exchange Act of 1934 has been declared effective by the SEC. However, the company cautioned that no final decision has been made regarding the proposed ADR uplisting. The SEC’s declaration of effectiveness does not constitute an endorsement or approval of CLINUVEL’s securities or a determination that the information in the registration statement is accurate or complete. The process remains subject to SEC rules and satisfaction of Nasdaq listing requirements, with no guarantee the uplisting will proceed or occur within the expected timeframe.

CLINUVEL Pharmaceuticals Limited has received a Notice of Compliance (NOC) from Health Canada for its novel drug SCENESSE (afamelanotide), authorizing the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The approval acknowledges compliance with Sections C.08.002 and C.08.005 of the Canadian Food and Drug Regulations, granting CLINUVEL the right to market the therapy in Canada. This regulatory milestone expands access to a treatment for a rare metabolic disorder that causes debilitating phototoxic reactions and burns following brief exposure to visible light.

Regulatory and Market Context

The Canadian approval follows previous marketing authorizations in Europe (2014), the U.S.A. (2019), and Australia (2020). SCENESSE is the only treatment for EPP to have received marketing authorisation from any regulatory body worldwide. CLINUVEL has established a network of Specialty Centers across North America, with five centers in Canada already trained and accredited to treat EPP patients. These centers have previously administered the drug under special access arrangements.

Clinical Profile and Usage

SCENESSE contains 16mg of the peptide afamelanotide, an analogue of a naturally occurring hormone that stimulates melanin production in the skin. The drug provides a photoprotective effect by preventing light penetration and acting as a strong antioxidant. Over 21,000 doses have been administered to EPP patients worldwide, with some patients receiving up to 20 years of continuous therapy. The drug is prescribed and administered exclusively by trained and accredited Specialty Centers in North America and EPP Expert Centres in Europe via subcutaneous implantation in an outpatient setting.

Safety and Adverse Events

The long-term safety profile of SCENESSE is a key differentiator, according to Dr. Dennis Wright, CLINUVEL’s Chief Scientific Officer. The most commonly reported adverse events in clinical trials include headaches, nausea, implant site reactions, oropharyngeal pain, cough, fatigue, skin hyperpigmentation, and dizziness. The company emphasized that data from global programs and postmarketing experience demonstrated the drug's safety and clinical benefit.

Company Overview

CLINUVEL is a global specialty pharmaceutical group focused on developing and commercialising treatments for genetic, metabolic, systemic, and life-threatening disorders. Headquartered in Melbourne, Australia, the company operates in Europe, Singapore, and the U.S.A. CLINUVEL is listed on the Australian Securities Exchange (ASX: CUV) and trades on other international exchanges.